



Incidence and Prevalence of Breast Cancer in USA

Anitha Sri S^{1*} and Prudhvi Raj P²

¹Department of Pharmaceutical Technology, GIET School of Pharmacy, AP, India

²Department of Pharmaceutics, Princeton College of Pharmacy, TS, India

*Corresponding author: Anitha Sri S, Department of Pharmaceutical Technology, GIET School of Pharmacy, AP, India, E-mail: anitha.suvvari@gmail.com

Received: December 28, 2016; Accepted: January 05, 2017; Published: January 10, 2017

Abstract

Breast Cancer is the cancer that develops in the breast tissue. It is the most common infiltrating cancer in females worldwide. It generally starts in the inner lining of milk lobules or the ducts that supply milk. **Cancer** arising in the milk lobules is known as **lobular carcinoma** whereas the cancer that develops in the milk ducts is known as **ductal carcinoma**. Obesity, lack of physical exercise, alcohol consumption, hormone replacement therapy and family history are the major causes of breast cancer. Females are more prone to breast cancer compared to males. Breast cancer accounts for 16% of cancers in females and 23% of **invasive cancers**. 18% of cancer deaths worldwide are due to breast cancer in both the genders. 5-10% of breast cancers are hereditary. One in every eight women in USA develops breast cancer in sometime of her life. Breast cancer is more common in white women but the mortality rate due to this cancer is more in black women.

Keywords: Breast cancer; Milk ducts; Awareness; Literature

Introduction

Breast Cancer, the term itself depicts the presence of carcinoma in the breast. Signs of breast cancer include the presence of lump in the breast, change in shape of the **breast**, discharge of fluids from the nipple, dimpling of skin and presence of red scaly patch on the skin of the breast [1-9]. Apart from ductal and lobular carcinomas, there exist 18 other subtypes of breast cancer. The severity of the cancer can be from low risk or no risk to death depending on the type of cancer, victim's age and extent of disease. Proper care must be taken, in order to prevent death of the patient [11-16]. So there exists a need to be educated and to obtain knowledge on **breast diseases** so that the right preventive measures can be taken during their occurrence. People can gain awareness through literature, internet sources, family physicians and consultants. **Open access journals** provide more visibility and accessibility to the readers in gaining the required information. The ongoing researches all over the world, which are being exhibited through open access journals, serve as the main source of information in various fields [17-19].

In order to create awareness among the people, group of physicians and consultants unite to form a **society** or an organization. The main aim of these societies is to counsel and create awareness among the victims of heart disorders as well as healthy personnel [20-26]. Major societies like **Senologic International Society** aims to improve public awareness in breast cancer

and the advancement of quality standards to enhance patient care. It also support and promote researches in the field of breast diseases. [World Academy of Medical Sciences \(WAMS\)](#) promotes the education and activities relating to the prevention and treatment of breast cancer and development of knowledge and practice in preventing breast cancer. [European Society of Oncology Pharmacy](#) of Czech Republic is associated with Omics thereby endorsing the scientific events conducted in the field of Oncology. Its main objective is to promote clinical and oncology pharmacy practice through - education and training, safe handling and administration of drugs, quality management, research and development and pharmaceutical care. [American Research and Policy Institute \(APRI\)](#) is a non-profit organization working with the aim to provide the useful and relevant information for enhancing women's health. This information can be utilized as reference by practitioners, policy makers etc. for promoting [health of women](#). The main objective of these societies is to disseminate the scientific knowledge to experts in the field so that they can provide better service to the patients and work together to reduce the risk of breast disorders. The society enables the understanding of the disorders by creating awareness among the global communities [27-34].

Open Access literature plays a key role in proving the information and current researches across the globe. [Breast Cancer: Current Research](#) provides information on latest advances in the treatment of breast cancer and also alternatives achieved for treating this cancer. [Journal of Women's Health, Issues and Care](#) a hybrid open access journal that publishes current trends in the research field and is a very good platform for the scholars to attain knowledge. It is a reliable source of information required to enhance women's health. [Women's Health and Breast Cancer](#) is an International meeting that is going to be held during October 2017 in Dubai [35-42]. All the themes pertaining to the preventives measures, other innovative techniques used in the current treatment process of breast cancer, women's health and issues will be presented. [Advances in Oncology Research and Treatments](#) is an international [peer-reviewed scholarly journal](#), which published the papers across the world on oncology [43-51].

[Gynecology & Obstetrics](#) Journal studies improve the knowledge and provide cutting-edge research strategies for the development of new therapeutics. [Journal of Oncology Translational Research](#) is a leading provider of information on cardiovascular diseases and novel methods of treatment followed. The above mentioned Open access journals are the peer-reviewed journals that maintain the quality and standard of the journal content, reviewer's agreement and respective editor's acceptance in order to publish an article. These journals ensures the barrier-free distribution of its content through online open access and thus helps in improving the citations for authors and attaining good [journal impact factors](#).

Types of Breast Cancer

Breast cancer is classified into different types based on the way the cancer cells look under microscope. Most common types of Breast cancer include: [Ductal carcinoma](#) and Lobular carcinoma. Less frequent breast cancers include inflammatory breast cancer, Paget disease of the nipple, Phyllodes tumor and [Angiosarcoma](#). [52-66].

Ductal carcinoma is also known as invasive or infiltrating carcinoma [67]. Through Open access healthcare literature provides information of novel researches ongoing in the current era. Here are the list of few articles which provide reports that are competent enough for a person to attain knowledge on breast cancer [68-74]. An article entitled [Pure Micro papillary Carcinoma of the Male Breast: Report of A Rare Case](#) written by Olfa El Amine El Hadj of Tunisia, explains a

rare type of breast cancer diagnosed in a male patient. A micro biopsy was performed and the final histopathology revealed a pure Micro papillary Carcinoma of the male breast in more than 50% of tumor's volume. Micro papillary Carcinoma is a special subtype of invasive ductal carcinoma with an aggressive nature. [Diagnosis](#) of this relatively rare carcinoma is important in predicting metastasis to lymph nodes and distant sites regardless of tumor size. Axillary and distant metastasis should be evaluated to determine the therapeutic strategy. [74-82]. [Kefah Mokbel](#) is an eminent expert in Breast cancer surgery. He stated that Ductal carcinoma in situ is a heterogeneous disease characterized by noninvasive clonal proliferation of malignant epithelial cells arising from the mammary ducts and terminal ductal-lobular units [83-91]. Its reported incidence is rising due to the wide adoption of screening mammography and magnetic resonance imaging (MRI) in his article entitled [Management of Ductal Carcinoma In situ](#) [92-96].

Lobular Carcinoma is also known as invasive or infiltrating carcinoma which starts in the lobules of the milk-producing glands. It is second most common type of carcinoma. According to American Cancer society more than 1,80,000 women in USA are prone to [Lobular Carcinoma](#). [97-104]. In a manuscript entitled Pleomorphic Lobular Carcinoma of the Breast authored by [Sandra Hatch](#) of USA provides data regarding breast cancer cases that were recorded in USA. Pleomorphic carcinoma is a subtype of Lobular Carcinoma [105-110]. Recent and innovative approaches that are taking place in the current emerging trend in treatment of breast cancer is going to be discussed at [International Meeting on Women's Health and Breast Cancer](#) which is going to be held in October 2017 in Dubai [111-118].

Apart from the articles, presentation at conferences, symposiums, workshops also yield a better exposure to health information and advanced technologies that are being invented in the present generation [119-123]. In [2nd World Congress on Breast Cancer](#) held in September 2016 in USA, the main topics like the biology, types, therapy, Chemotherapy, Screening and diagnosis, therapeutic approaches, side effects, etc. were discussed [124-129]. Shahla Masood, an expert in breast pathology had discussed the ways that can be monitored to reduce the risk of breast cancer. At [World Congress on Midwifery and Women's Health](#) held in August 2016 in USA, the scientific lectures delivered have discussed one of the most challenging burdens of the recent times. Lisa A. Quinn was one of the eminent speakers at the conference and discussed all the themes pertaining to [women's health](#) [130-136].

Diagnosis of Breast Cancer

The incubation of rat kidney microsomes in the presence of Ascorbate-Fe⁺⁺ resulted in the peroxidation of membranes as evidenced by emission of light (chemiluminescence). After incubation of microsomes in an Ascorbate-Fe⁺⁺ system at 37°C for 180 min, the cpm originated from light emission was lower (concentration dependent) in the SM group than in the control group. FIG. 2 shows the light emission obtained from SM group and control group. The values were from 1768.3 ± 201.19 in the control group to 549.33 ± 15.27 cpm with the addition of 50 µg of SM/mg prot.

Doctors use many tests to detect the presence of [breast cancer](#) as well as to identify whether the cancer is confined to breast and lymph nodes or it has spread to other parts of the body [137-145]. [Imaging Tests](#) like Diagnostic Mammography, [Ultrasound](#) and MRI are used frequently to detect the cancer of the breast. [Biopsy](#) is another widely used technique for the diagnosis of breast cancer [146-158]. Biopsy is removal of small amount of tissue for examination under a microscope for the presence of cancer. Other tests include X-ray, Bone scan,

[Computed tomography](#) commonly known as CT scan, Positron emission tomography known as PET scan [159-165].

Management and Treatment of Breast Cancer

As the breast diseases have become more prevalent, there are many scientific professionals are trained especially in detecting, treating and counseling the prevention of [Breast cancers](#) and these professionals are well known as Oncologists. There exists almost 11,650 doctors specialized in breast cancer treatment, in USA as per a survey conducted in April 2016 [166-173]. The management of breast cancer depends on the type, and stage of the cancer as well as the age of the patient. Breast cancer is generally treated with surgery and later followed by [Chemotherapy](#) or radiation. The common surgeries of breast cancer include: [Mastectomy](#), Quadrantectomy and Lumpectomy. Chemotherapy is mostly used at the stage of 2-4. [Radiation](#) is given after the surgery to remove the microscopic tumour cells of the breast that escaped the during the surgery. [174-186]. [Luca Morandi](#) is a scientific professional with research expertize in breast diseases. Peter has presented the genetic clonal mapping of ductal carcinomas that are not differentiated in his article Genetic clonal mapping of in situ and invasive ductal carcinoma indicates the field cancerization phenomenon in the breast [187-193]. [Alejandra de Andres Gomez](#) holds expertize in Breast Cancer and surgery. In her article entitled The Challenge of pN3 Stage in Breast Cancer she had discussed the prognosis as well as the TNM staging of breast cancer [194-200].

Conclusion

Breast Cancers are most prominent and prevalent in USA. Many innovative technologies have been developed to reduce the mortality due to breast disorders. [Novel investigations](#) include the development of novel drug therapies as well as cancer therapies. [Cryoablation](#) is another type of novel technology developed and must be further studied whether it can be used as a substitute for Lumpectomy.

REFERENCE

1. Maksym P, Starodub N, Bilko N. Determination of the Concentration of Polyamines with SPR-based Immune Biosensor for Early Diagnostics of Breast Cancer. J Biosens Bioelectron. 2016;7:227.
2. Relvas A, Sá MM, Leandro S. When Breast Cancer is In. J Clin Case Rep. 2016;6:890.
3. Xu J, Zhou Y, Wang Y, Zhang H. Clinical Evaluation of Ultrasound- Guided Thoracic Paravertebral Block (TPVB) Effect on Postoperative Analgesia in Patients with Breast Cancer after Radical Mastectomy. Primary Health Care. 2016;6:247.
4. Raquel CC, Aurora LV. Delaying Radiotherapy and Risk of Recurrences in Patients with Breast Cancer Stage I And II. A Retrospective Observational Study. Breast Can Curr Res. 2016;1:116.
5. Aljohani S, Saib I, Noorelahi M. Women's Performance of Breast Cancer Screening (Breast Self-Examination, Clinical Breast Exam and Mammography). J Health Educ Res Dev. 2016;4:202.
6. Gomez AA, Jurado RZ, Diana CF. The Utility of Mammi-Pet in Multifocal Breast Cancer. Breast Can Curr Res. 2016;1:101.
7. Al-Bader SB, Bugrein H, Elmistiri M, Alassam T. The Development of Breast Cancer Screening in Qatar (January 2008 – April 2015). Evid Based Med Pract. 2016;1:107.
8. Grant J, DiCarlo C, Woessner-Hoyson J. Importance of a Multidisciplinary Approach to Breast Cancer Treatment in Pregnancy: Case Report of New Diagnosis of Pregnancy-Associated Breast Cancer. J Carcinog Mutagen. 2016;7:279.

9. Khedr RAE, Ghannam AAE. A Clinical Phase II Study of Oral Vinorelbine in HER-2 Negative Metastatic Breast Cancer. *J Cancer Sci Ther.* 2016;8:262-267.
10. Osman MAA, Hamid ME, Satti AH, et al. High Concentration of Tumor Marker Cancer Antigen CA15-3 in Breast Cancer Patients after Surgery. *Breast Can Curr Res.* 2016;1:114.
11. Blair S, Robles J, Weiss A, Ward E, Unkart J (2016) Treatment of Breast Cancer in Women Aged 80 and Older: A Systematic Review. *Breast Can Curr Res.* 2016;1:115.
12. Cazzaniga M, Riva F, Cicchiello F. Metronomic Oral Combination of Vinorelbine and Capecitabine in Advanced Breast Cancer: is it Time to be Considered for Daily Clinical Practice?. *J Cancer Clin Trials.* 2016;1:119.
13. Prasad P, Shayne M. Effect of Dietary Soy on Breast Cancer Recurrence and Mortality: A Review. *J Nutr Food Sci.* 2016;6:563.
14. Wang Y, Zou W. ER- α 36, A Novel Biomarker for ER-Negative Breast Cancer. *Mol Biol.* 2016;5:e138.
15. Seddik Y, Brahmi SA, Al-Jarroudi O, et al. Choroidal Metastasis as a First Sign of Recurrence in a Patient with Breast Cancer: A Case Report. *Breast Can Curr Res.* 2016;1:112.
16. Louis R, Louis E, Stinkens K, et al. (2016) Metabolic Phenotyping of Blood Plasma by Proton Nuclear Magnetic Resonance to Discriminate between Colorectal Cancer, Breast Cancer and Lung Cancer. *Metabolomics (Los Angel).* 2016;6:187.
17. Namini SN. Systematic Review of the Risk of Permanent Alopecia with Docetaxel Treatment for Breast Cancer. *J Clin Case Rep.* 2016;6:851.
18. Kitsera N, Shparyk YA, Helner N, et al. Detection of Gene Mutation in the 185del AG BRCA1 in Families with Hereditary Breast Cancer. *Hereditary Genet.* 2016;5:171.
19. Mori R, Futamura M, Morimitsu K, et al. Effective Hormone Therapy Reduces the Efficacy of Subsequent Chemotherapy in Hormone-Receptor-Positive Metastatic Breast Cancer. *Chemo Open Access;* 2016;5:210.
20. Hassanen EM, Zamzam ML, Elbahai AM, et al. Comparative Study between Vinorelbine based Versus Taxanes based Chemotherapy in Treatment of Parenchymal Metastatic Breast Cancer. *Chemo Open Access.* 2016;5:208.
21. Gomez ADA. The Challenge of pN3 Stage in Breast Cancer. *Breast Can Curr.* 2016;1:e103.
22. Manna E, Maiti S, Bhattacharyya S, et al. Early Detection of Breast Cancer: Management with Radiotherapy associated with Cardiovascular Disease (CVD), Heart Failure among the Breast Cancer Survivors Woman. *J Women's Health Care.* 2016;5:323.
23. Khedr RAE, Ghannam AAE, El-Rashidy MA, et al. The Prognostic Role of Tumor-Infiltrating Lymphocytes CD8 and Foxp3 and their Impact on Recurrence in Breast Cancer Patients. *J Cancer Sci Ther.* 2016;8:206-212.
24. Chen YC, Lai HW, Wang WC, et al. Validation of Breast Cancer Survival Prediction Model with SEER Database. *J Integr Oncol.* 2016;5:174.
25. Mehta P, Purohit M. Kernel Oriented Multivariate Feature Selection for Breast Cancer Data Classification via MRMR Filter. *J Health Med Informat.* 2016;7:239.
26. Peretti A, Amenta F. Breast Cancer Prediction by Logistic Regression with CUDA Parallel Programming Support. *Breast Can Curr Res.* 2016;1:111.
27. Gopal SH, Das SK. Role of Lactoferrin in the Carcinogenesis of Triple-Negative Breast Cancer. *J Cancer Clin Trials.* 2016;1:e105.
28. Verna V, Mary-Ann D. Aspergillus Lymphadenitis Mimicking Cervical Lymph Node Recurrence in a Breast Cancer Patient. *J Med Diagn Meth.* 2016;5:220.

29. Agboola AO, Ebili HO, Iyawe VO, et al. Cadherin Expression in the Nigerian and United Kingdom Breast Cancer Cases: A Comparison of Clinicopathological and Prognostic Characteristics. *Surgery Curr Res.* 2016;6:271.
30. Rahayuwati L, Ibrahim K, Mardiah W. Health Seeking Behavior on Breast Cancer Therapies: Patients' versus Providers' Views. *J Comm Pub Health Nurs.* 2016;2:129.
31. Nagata T, Shimada K, Long XL, et al. KLF4 Improve Prognosis of Triple-negative Breast Cancer by Suppression of Epithelial-mesenchymal Transition. *Breast Can Curr Res.* 2016;1:110.
32. Honório M, Guerra-Pereira N, Silva J, et al. Decreased Survival in African Patients with Triple Negative Breast Cancer. *J Palliat Care Med.* 2016; 6:270.
33. Hebert M, Gallagher F, ST-Cyr Tribble. A Grounded Theory Exploring the Health Status Perceptions Shift of Women Living with Breast Cancer. *Breast Can Curr Res.* 2016;1:109.
34. Li Y, Chen H, Cao L, et al. A Survey of Computer-aided Detection of Breast Cancer with Mammography. *J Health Med Informat.* 2016;7:238.
35. Naeini EE, Zaker BS, Peyvandy P. The Effectiveness of Stress Management Training on Hardiness in Patients with Breast Cancer. *Abnorm Behav Psychol.* 2016;2:115.
36. Hara F, Takashima T, Tsurutani J, et al. Randomized, Optimal Dose Finding, Phase II Study of Tri-Weekly Nab-Paclitaxel in Patients with Metastatic Breast Cancer (ABROAD). *J Clin Trials.* 2016;6:267.
37. Hatch SS. Triple Negative Breast Cancer: It's Time to Kick the Can down the Road. *Oncol Trans Res.* 2016;2:e101.
38. Lagiou M, Poumpouridou N, Goutas N, et al. Molecular Analysis of RASSF1 Gene Methylation and mRNA Expression in Sporadic Breast Cancer. *Clin Med Biochemistry Open Access.* 2016;2: 118.
39. Rashid OM, Maurente D, Takabe K. A Systematic Approach to Preclinical Trials in Metastatic Breast Cancer. *Chemo Open Access.* 2016;5: 204.
40. Bila A, Gramatiuk S. To Compare the Mitochondrial Complex between Metastasis Breast Cancer and Patients with Breast Cancer and Hepatitis C Virus. *J Women's Health Care.* 2016;5:315.
41. Kinoshita S, Fukushima N, Miyake R, et al. Clinicopathological Assessment of Patients with Locally Advanced Breast Cancer with 10 or More Lymph Node Metastases. *Breast Can Curr Res.* 2016;1:107.
42. Omran M, Badary O, Helal A, et al. A Prospective Pharmacokinetic Study of Docetaxel in Breast Cancer Patients in Relation to CYP3A4 Activity. *Clin Pharmacol Biopharm.* 2016;5: 156.
43. Li T, Yang M, Ren C, et al. Combination of Nab-Paclitaxel with Trastuzumab as Neoadjuvant Chemotherapy for HER2- positive Breast Cancer Patients: Experience from a Single Center. *Clin Exp Pharmacol.* 2016;6:209.
44. sman U, Gilbert CR. Bronchial Necrosis Following Bevacizumab and Stereotactic Body Radiotherapy for Treatment of Metastatic Breast Cancer. *J Pulm Respir Med.* 2016;6: 345.
45. Grondona JP, Hannois A, Bracco RA, et al. Hepatic Resection for Breast Cancer Liver Metastases . *J Cancer Clin Trials.* 2016;1:110.
46. Dogan S, Kurtovic-Kozaric A, Karli G. The Detection of Extremely High and Low Expressed Genes by EGEF Algorithm in Invasive Breast Cancer. *J Biom Biostat.* 2016;7: 286.
47. Sinha S, Nath J, Mukherjee A, et al. Predictive and Prognostic Factors in Breast Cancer and their Association with ER PR HER2/neu Expression. *J Carcinog Mutagen.* 2016;7:263.
48. Rios SSD, Chen ACR, Chen JR, et al. Wearing a Tight Bra for Many Hours a Day is Associated with Increased Risk of Breast Cancer. *Adv Oncol Res Treat.* 2016;1: 105.
49. Luo S, Li Q, Chen J, et al. Two Novel Curcumin Analogues Induced Reactive Oxygen Species Generation and Mitochondrial-Related Apoptosis in Human Breast Cancer MCF - 7 Cells. *J App Pharm.* 2016;8:215.
50. Ian SF. Medico-legal Aspects of Delay in Diagnosis of Breast Cancer. *Can Surg.* 2016;1: 103.

51. Taira N, Fujisawa T, Araki K, et al. Cohort Study of Secondary Endocrine Therapy in Metastatic Breast Cancer with a Poor Response to Initial Endocrine Therapy. *J Clin Trials*. 2016;6:260.
52. Aydin AS, Gunduz UR, Yalcinkaya S, et al. A Rare Case of Primary Breast Cancer with Isolated Renal Parenchymal Metastasis Mimicking Primary Renal Cell Carcinoma. *J Clin Case Rep*. 2016;6:724.
53. Lucibello M, De Braud F. Phospho-TCTP and Dihydroartemisinin: A Novel Therapeutic Opportunity in Advance Breast Cancer. *Chemo Open Access*. 2016;5:196.
54. García-Novoa A, Acea-Nebril B. Controversies in Axillary Treatment of Breast Cancer Patients and Metastatic Sentinel Lymph Node. *J Cancer Sci Ther*. 2016;8:066-068.
55. Ofor O, Moor H, Humber D, et al. CTCF May Not Directly Regulate ERα mRNA Expression in the ER+ MCF7 Breast Cancer Cell Line. *J Cancer Sci Ther*. 2016;8:059-065.
56. Shahbazi S, Kuanar K, Gade DR, et al. Semiempirical Investigation of the Postmenopausal Breast Cancer Treatment Potential of Xanthone Derivatives. *Nat Prod Chem Res*. 2016;4:206.
57. Olaya N, Corredor A, Gutierrez MF. Bovine Leukemia: Zoonosis Associated with Breast Cancer in Humans?. *J Med Surg Pathol*. 2016;1:110.
58. Minafra IP, Cara GD, Musso R, et al. Proteomic Profiling of In-Vitro Bone-Conditioned Skbr3 Breast Cancer Cells. *J Proteomics Bioinform*. 2016;9:075-083.
59. Mukherjee G, Lakshmaiah KC, Vijayakumar M, et al. Analysis of Clinico-Pathological Characteristics of Indian Breast Cancers Shows Conservation of Specific Features in the Hormone Receptor Sub-Types. *J Integr Oncol*. 2016;5:159.
60. Osaki A. Adjuvant Chemotherapy with S-1 in Breast Cancer Patients after Primary Systemic Chemotherapy. *Chemo Open Access*. 2016;5:187.
61. Ondimu TO, Amimo FA, Odado PS, et al. Factors that Influence the Uptake of Breast Cancer Screening among Secondary School Student: Case of Kisii South Sub-County Kenya. *Oncol Cancer Case Rep*. 2016;2:109.
62. Smichkoska S, Lazarova E. Long Term Trastuzumab in Metastatic Setting of the Patients with HER2 Positive Breast Cancer. *J Blood Lymph*. 2016;1:103.
63. Colone M, Kaliappan S, Calcabrini A, et al. (2016) Redox-active Microcapsules as Drug Delivery System in Breast Cancer Cells and Spheroids. *J Mol Genet Med*. 2016;10:200.
64. Kadmon I. Breast Cancer - A Developing Paradigm of Nursing Care in Israel. *J Nurs Care*. 2016;5:331.
65. Grech G, Baldacchino S, Saliba C, et al. Molecular Classification of Breast Cancer Patients Using Formalin-fixed Paraffin-embedded Derived RNA Samples. *J Mol Biomarkers Diagn*. 2016;S8:016.
66. Dehbid M, Aleyasin SA, Vaziri H. Evaluation of DNA Methylation of MAP9 Gene in Breast Cancer as Epigenetic Biomarker. *J Mol Biomarkers Diagn*. 2016;S8:015.
67. El-Lathy HA, Dohal AA, Abbas AE. The Impact of Pretreatment 18F-FDG (PET/CT) Maximum Standardized Uptake Value and Neutrophil/Lymphocyte Ratio (NLR) in Predicting Prognosis in Surgically Treated Oligometastatic Breast Cancer Patients. *J Nucl Med Radiat Ther*. 2015;7:271.
68. Wang HH, Ho CR, Chung UL Long-Term Survivors of Breast Cancer: Religious Influence. *J Nurs Care*. 2016;5:324.
69. Kabel AM, El-Rashidy MA, Omar MS. Ameliorative Potential of Tamoxifen/Thymoquinone Combination in Patients with Breast Cancer: A Biochemical and Immunohistochemical Study. *Cancer Med Anticancer Drug*. 2016;1:102.
70. Jehn CF, Flath B, Nogai H, et al. Impaired Thinking in Patients with Breast Cancer and Depression. *J Palliat Care Med*. 2016;6:248.

71. Bates E, Wallace DR. Differential Effects of Organic and Inorganic Mercury on Phenotypically Variant Breast Cancer Cell Lines. *J Clin Toxicol*. 2015;5:273.
72. Jyoti BS. Accuracy of MRI for Prediction of Response to Neo-Adjuvant Chemotherapy in Triple Negative Breast Cancer Compared to Other Molecular Types. *Chemo Open Access*. 2015;5:175.
73. Castillo AF, Orlando UD, Lopez P, et al. Gene Expression Profile and Signaling Pathways in MCF-7 Breast Cancer Cells Mediated by Acyl-Coa Synthetase 4 Overexpression. *Transcriptomics*. 2015;3:120.
74. Vohra LM, Siddiqui T. Metaplastic Breast Cancer and p16 Positivity: What Does It Mean?. *J Carcinog Mutagene*. 2015;6:244.
75. Akasbi Y, Arifi S, Najib R, et al. An Unusual Case of Multiple Primary Carcinomas: Breast Cancer and Rectal Adenocarcinoma in a Single Patient: Report of a Case and Review of the Literature. *Arch Surg Oncol*. 2015;1:107.
76. Zhong GX, Wu ZY, Zhu X, et al. The Molecule Mechanisms of Bone Metastasis in Breast Cancer. *J Orthop Oncol*. 2015;1:102.
77. Steponkiene S, Dapkute D, Riekstina U, et al. Accumulation and Distribution of Non-targeted and Anti-Cd44-conjugated Quantum Dots in Distinct Phenotypes of Breast Cancer. *J Nanomed Nanotechnol*. 2015;6:341.
78. Xu X. Molecular Mechanisms Underlying Chemotaxis in the Model System Dictyostelium discoideum and Mammalian Neutrophils and Breast Cancer Cells. *Cell Dev Biol*. 2015;4:e135.
79. Das U, Lakshmaiah KC, Lokanatha D, et al. Breast Cancer in Women of Younger than 35 Years: A Single Center Study. *J Mol Biomark Diagn*. 2015;6:261.
80. Basu A, Moirangthem A. Advances of Non-Surgical Therapy for Different Molecular Subtypes of Breast Cancer. *Adv Genet Eng*. 2015;4:132.
81. Vargens OMC, Berterö CM. Defining Contentment in Quality of Life in the Context of Breast Cancer Experience: A Meta-Synthesis. *J Palliat Care Med*. 2015;5:239.
82. Das SK, Ratna A. Endothelin: Ominous Player in Breast Cancer. *J Cancer Clin Trials*. 2015;1:e102.
83. Singh A, Arora D. A Case of Breast Cancer Recurrence at the "Match Line". *J Blood Lymph*. 2015;1:101.
84. Yadav AK, Jha V. Metagenomic Analysis of Molecular Profile of Breast Cancer Using Genie a Literature Based Gene Prioritizing Tool: A Novel Approach. *Adv Tech Biol Med*. 2015;3:147.
85. Koo J, Schramm L. Soy and Breast Cancer, have we Analyzed all the Risks?. *J carcinog Mutagene*. 2015;6:e117.
86. Bahri S, Kain TS, Mehta RS, et al. Initial Experience of Monitoring Response of Breast Cancer to Bevacizumab-containing Chemotherapy using A New Integrin Specific PET Imaging Tracer [F-18]RGD-K5. *J Mol Imag Dynamic*. 2015;5:116.
87. Noro J, Maciel J, Duarte D, et al. Evaluation of New Naphthalimides as Potential Anticancer Agents against Breast Cancer MCF-7, Pancreatic Cancer BxPC-3 and Colon Cancer HCT-15 Cell Lines. *Organic Chem Curr Res*. 2015;4:144.
88. Puckett Y, Abedi M, Alavi-Dunn N, et al. Does Offering Free Breast Cancer Screenings Make a Difference?— A Retrospective 3-Year-Review of a West Texas Free Breast Cancer Screening Program. *J Cancer Diagn*. 2016;1:101.
89. Chernyy VS, Gulyaeva LF, Kozlov VV. Expression of Steroid Receptors and Cytokeratin 18 in Breast Cancer after Neoadjuvant Chemotherapy. *J Mol Biomark Diagn*. 2015;S2:013.
90. Jayanthi M, Venkatesh P, Thirunavukkarasu SV. Study on Blood Parameters of Tetrahydropyrimidine Carboxamide Derivatives on Breast Cancer. *J Develop Drugs*. 2015;4:135.
91. Yeh CH, Chien LC, Glick RM, et al. Auricular Point Acupressure (APA) to Manage a Symptom Cluster of Pain, Fatigue, and Disturbed Sleep in Breast Cancer Patients: A Pilot Study. *J Pain Relief*. 2015;4:199.

92. Messersmith L, Singer J, Ciesemier G. Utilization of the Breast Cancer Risk Assessment Tool in the Identification and Screening of Women at Increased Risk of Breast Cancer. *J Women's Health Care*. 2015;4:259.
93. Nam MN. Gene Signature: A Guideline for Hormonal Therapy in Breast Cancer. *J Steroids Hormon Sci*. 2015;6:e115.
94. Liang DH, El-Zein R, Dave B. Autophagy Inhibition to Increase Radiosensitization in Breast Cancer. *J Nucl Med Radiat Ther*. 2015;6:254.
95. Dani M, Pinder S, Baum M, et al. A Long Breast Cancer Remission without Standard Therapy. *J Clin Case Rep*. 2015;5:569.
96. Chai S, Fan P. Mechanistic Progress of Estrogen-induced Apoptosis in Estrogen-deprived Breast Cancer Cells. *J Cell Sci Ther*. 2015;6:218.
97. Roy M, Sarkar R, Mukherjee S, et al. Sulforaphane Inhibits Metastatic Events in Breast Cancer Cells through Genetic and Epigenetic Regulation. *J Carcinog Mutagen*. 2015;6:231.
98. Timpe LC, Li D, Yen TY, et al. Mining the Breast Cancer Proteome for Predictors of Drug Sensitivity. *J Proteomics Bioinform*. 2015;8:204-211.
99. Lombardi MG, Salamone G, Gori S, et al. Cholinergic Actions of Autoantibodies from Breast Cancer Patients on Dendritic Cells. *J Clin Cell Immunol*. 2015;6:340.
100. Petersen I, Kollek R. The Symbolic Relevance of Feedback: Return and Disclosure of Genomic Research Results of Breast Cancer Patients in Belgium, Germany and the UK. *J Clinic Res Bioeth*. 2015;6:230.
101. Mezzaroma E, Weiss E, Mikkelsen R, et al. Disentangling the Mechanisms of Radiation-Induced Heart Disease in the Treatment of Breast Cancer. *Transl Med*. 2015;5:152.
102. Xiangpo P, Shuzhen L, Jianfeng G, et al. Current Evidence on the Association between Four Polymorphisms in the Matrix Metalloproteinases (MMP) Gene and Breast Cancer Metastasis. *J Environ Anal Chem*. 2015;2:151.
103. Lorca AM, Gallego A, Escabias C, et al. Value of 18F-FDG-PET/CT Initial Staging in No Metastatic Breast Cancer with Poor Prognostic Factors. *OMICS J Radiol*. 2015;4:201.
104. El-Lathy HA, Dohal AA, Alassiri Y, et al. The Prognostic Role of Pretreatment 18F-FDG (PET/CT) Maximum Standardized Uptake Value in Multiple or Oligometastatic Breast Cancer Patients. *J Nucl Med Radiat Ther*. 2015;6:236.
105. Rawat K, Haq W, Tripathi RK. BTF3-Promoter Based In Vitro Screening of Anti- Human Breast Cancer Compounds. *Clin Exp Pharmacol*. 2015;5:183.
106. Retsky M. Omics Conferences and Breast Cancer in Sub-Saharan Africa. *J Bioequiv Availab*. 2015;7:e66.
107. Porchia LM, Gonzalez-Mejia ME, Calderilla-Barbosa L, et al. Common BRCA1 and BRCA2 Mutations among Latin American Breast Cancer Subjects: A Meta-Analysis. *J Carcinogene Mutagene*. 2015;6:228.
108. Abdulrahman GOJ. Targeted Therapies in the Management of Breast Cancer. *J Integr Oncol*. 2015;4:137.
109. Hall JM, Robinson ML. Peroxisome Proliferator-Activated Receptor γ as a Therapeutic Target in Human Breast Cancer. *J Steroids Hormon Sci*. 2015;6:155.
110. Nahleh Z, Otoukesh S. Celebrating Cancer Survivorship- A focus on Breast Cancer . *J Psychol Psychother*. 2015;5:182.
111. Liu G, Ren S, Yan Y, et al. Comparisons of the Clinicopathological Characteristics and the Expression of Tumor Biomarkers among Luminal, HER2-Enriched and Triple Negative Breast Cancer. *Gen Med (Los Angel)*. 2015;3:184.
112. Zhu C, Cui L. The Role of Ahr in Anticancer Drug Resistance in Breast Cancer. *J Bioanal Biomed*. 2015;7:087-090.

113. Khosroshahi ME, Ghazanfari L, Hassannejad Z, et al. In-vitro Application of Doxorubicin Loaded Magnetoplasmonic Thermosensitive Liposomes for Laser Hyperthermia and Chemotherapy of Breast Cancer. *J Nanomed Nanotechnol.* 2015;6:298.
114. Yu X, Yin M, Su Z, et al. TGF beta Exposure Promotes Acquisition of Epithelial-like Phenotype in Breast Cancer Spheres. *J Cytol Histol.* 2015;S3:014.
115. Stötzer OJ, Lehner J, Braun M, et al. Circulating Cell Free DNA as Blood Based Biomarker in Breast Cancer. *Mol Biol.* 2015;3:120.
116. Charushila YK, Subodhini AA. Evaluation of Serum Antioxidants during Adjuvant Chemotherapy of Breast Cancer- A Prospective Observational Study. *Biochem Anal Biochem.* 2015;4:171.
117. Andrea CG, Luca FG. Complete Response in Patient with Metastatic Breast Cancer Treated with Metronomic Chemotherapy. *J Blood Lymph.* 2015;5:136.
118. Xu W. Targeting Membrane-Bound GRP78 Protein (Arrow) on the GFP-labelled Breast Cancer Cell Surface (Green) by the Quantum Dot-Conjugated Anti-GRP78 ScFv Antibody (Red). *Single Cell Biol.* 2015;4:i101.
119. Ahmad A, Sheikh S, Ali SM, et al. Nanosomal Paclitaxel Lipid Suspension Demonstrates Higher Response Rates Compared to Paclitaxel in Patients with Metastatic Breast Cancer. *J Cancer Sci Ther.* 2015;7:116-120.
120. Garrison JB, Ge C, Che L, et al. Knockdown of the Inhibitor of Apoptosis BRUCE Sensitizes Resistant Breast Cancer Cells to Chemotherapeutic Agents. *J Cancer Sci Ther.* 2015;7:121-126.
121. Jones B, Eliasziw M, Eigl BJ, et al. A Comparison of Incremental Costs of Breast Cancer Clinical Trials to Standard of Care. *J Clin Trials.* 2015;5:216.
122. Sennerstam RB, Strömberg JO. Genomic Instability or One-Gene Theory for Tumor Progression: A Breast Cancer Study. *J Carcinogene Mutagene.* 2015;6:223.
123. Kerivan L, Reintgen M, Reintgen E, et al. Male Breast Cancer. *J Clin Exp Oncol.* 2016;5:4.
124. Usta A, Asmatulu R. Synthesis and Analysis of Electrically Sensitive Hydrogels Incorporated with Cancer Drugs. *J Pharm Drug Deliv Res.* 2016;5:2.
125. Guest TC, Rashid S. Anticancer Laccases: A Review. *J Clin Exp Oncol.* 2016;5:1.
126. Rhoten BA, Radina ME, Adair M, et al. Hide and Seek: Body Image-Related Issues for Breast Cancer Survivors with Lymphedema. *J Womens Health, Issues Care.* 2016;4:2.
127. Eljedi A, Nofal M. Health-Related Quality of Life and its Influencing Factors among Breast Cancer Patients in Palestine. *J Womens Health, Issues Care.* 2014;3:5.
128. Madsen MT, Hansen MV, Wildschjødtz G, et al. Actigraphy can be used to Quantify Sleep in the Perioperative Period in Women Undergoing Breast Cancer Surgery: A Validation Study. *J Sleep Disor: Treat Care.* 2014;3:4.
129. Araújo DV, Costa RHS, Justino DCP, et al. Evaluation of Sleep Quality in Patients with Breast Cancer. *J Sleep Disor: Treat Care.* 2014;3:4.
130. Lima FPA, Lotufo ADP, Minussi CR, et al. Artificial Immune Systems with Negative Selection Applied To Clinical Diagnosis of Breast Cancer Samples. *J Comput Eng Inf Technol.* 2014;3:1.
131. Ginter AC, Braun B. Female Breast Cancer Patients' Need for Social Support: Implications for Patients without Partners and Health Care Professionals. *J Womens Health, Issues Care.* 2014;3:3.
132. Atalay C, Guler SA, Selamoglu D, et al. Impact of Loco-Regional Under-treatment in Elderly Patients with Early Breast Cancer (Protocol Yameka-09sdlit); Multi-Centric Retrospective Cohort Study. *J Clin Exp Oncol.* 2014;3:1.
133. Savitri SC, Cindy G. Breast Cancer Survivorship – Optimizing Follow-up Care: Patients' Perspectives of their Practical Needs. *J Womens Health, Issues Care.* 2014;3:1.

134. Alipour S, Eskandari A. Perspectives of Maternity after Breast Cancer. *Androl Gynecol: Curr Res.* 2013;2:1.
135. Merten JW, Walsh-Childers K, Rodman L, et al. Rural Breast Cancer Patients and Survivor's Perspectives using Online Health Resources. *J Womens Health, Issues Care.* 2013;2:6.
136. Mahapatra S, Kar A, Das U, et al. Glomus Tumor in Vulva with Uncertain Malignant Potential. *J Womens Health, Issues Care.* 2013;2:5.
137. Abolfotouh MA, Abulkhair O, Sbitan SE, et al. Case-control Study of Breast Cancer and Dietary Fat Intake in Saudi Females. *J Womens Health, Issues Care.* 2013;2:5.
138. Shah C, Badiyan S, Khwaja S, et al. Breast Cancer Related Lymphedema: A Review of Recent Developments. *Androl Gynecol: Curr Res.* 2013;1:2.
139. Ngai SC. Epigenetics Interplay between DNA Methylation and Histone Modifications in Breast Cancer. *Adv Genet Eng Biotechnol.* 2012;1:1.
140. Rahbar A. Promotion of Tumorigenesis and Clinical Implications of Viral Infection in Breast Cancer. *J Carcinog Mutagen.* 2015;6:217.
141. Cao Q, Heath J, Heath J, et al. Pulmonary Metastasis on TC-99m MDP Bone Scan Mimicking Metastatic Rib Lesions in Breast Cancer. *J Nucl Med Radiat Ther.* 2015;6:213.
142. Malki A, Mohsen M, Aziz H. "Breakthrough Therapies" for Breast Cancer Metastasis. *J Genet Syndr Gene Ther.* 2015;6:e131.
143. Tsuda B, Kametani Y, Miyamoto A, et al. The Effect of Peptide Treatment on the HLA-Binding and Antibody Production in Peripheral Blood Mononuclear Cells Obtained from Japanese Breast Cancer Patients. *J Vaccines Vaccin.* 2015;6:270.
144. Singal R, Narang D, Dang R, et al. Awareness and Follow up of Breast Cancer in a Young Female. *J Health Med Informat.* 2015;6:181.
145. Perfilyeva Y, Ostapchuk Y, Cetin EA, et al. Hyaluronan-Binding T Regulatory Cells in Peripheral Blood of Breast Cancer Patients. *J Clin Cell Immunol.* 2015;6:286.
146. Ichihara H, Yamasaki S, Hino M, et al. Hybrid Liposomes inhibit the Growth and Angiogenesis in Human Breast Cancer Model. *J Carcinog Mutagen.* 2015;6:207.
147. Banning M. Pakistani Women's Perceptions and Experiences of the Psychological Impact of Advanced Breast Cancer. *Primary Health Care.* 2014;4:163.
148. Toulba A, Iraqi M, Mouhajir N, et al. The Additional Irradiation of the Tumor Bed "The Boost" In the Breast Cancer Conservative Treatment: What Techniques?. *J Nucl Med Radiat Ther.* 2015;6:207.
149. Santucci-Pereira J, Barton M, Russo J. Use of Next Generation Sequencing in the Identification of Long Non-Coding RNAs as Potential Players in Breast Cancer Prevention. *Transcriptomics.* 2014;2:104.
150. Hummeida ME, Salah R, Hussien I, et al. Ultrasonographic Appearance of the Uterine Endometrium in Sudanese Breast Cancer Women on Tamoxifen Therapy. *J Women's Health Care.* 2015;4:215.
151. Nichols EM, Cohen RJ, Cheston SB, Feigenberg SJ (2014) Radiation Therapy in the Elderly with Early Stage Breast Cancer: Review and Role of New Technology. *J Nucl Med Radiat Ther* 5:204.
152. Kalos DR, Lund ME, Visco DP, et al. Intraoperative Radiation Therapy for Breast Cancer Not Associated with Pulmonary Complications. *J Nucl Med Radiat Ther.* 2014;6:198.
153. Wesolowski R, Carson WE. Tumor Infiltrating Lymphocytes – The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer. *J Carcinog Mutagen.* 2014;5:199.
154. Filion M, Provencher L, Doyle C, et al. Survival Rate of Breast Cancer Patients who Participated in Clinicals Trials Versus those who did not. *J Clin Trials.* 2014;4:193.

155. Albarracin C, Dhamn S. Evolving Role of Ki67 as a Predictive and Prognostic Marker in Breast Cancer. *J Clin Exp Pathol.* 2014;4:e117.
156. Karasawa K, Fujita M, Shoji Y, et al. Biological Effectiveness of Carbon-Ion Radiation on Various Human Breast Cancer Cell Lines. *J Cell Sci Ther.* 2014;5:180.
157. Ahmed I, Ahmad U, Keong YY, et al. Induction of Nitric Oxide and TNF-A in Newcastle Disease Virus (NDV) AF2240 Infected RAW 264.7 Macrophages and their Cytotoxic Activity on MDA-MB-231 Breast Cancer Cell Line. *J Cancer Sci Ther.* 2014;6:478-482.
158. Aly R, Yousef A, Elbably O. Association of ABO Blood Group and Risk of Breast Cancer. *J Blood Disord Transfus.* 2014;5:241.
159. Boekhout AH, Werkhoven ED, Liebergen R, et al. Factors Affecting Long-Term Safety of Trastuzumab in Patients with Early HER2-Positive Breast Cancer. *Adv Pharmacoepidemiol Drug Saf.* 2014;3:160.
160. Telang N. Cellular Metabolism of Estradiol in Models for Select Molecular Subtypes of Clinical Breast Cancer. *J Steroids Hormon Sci.* 2014;5:143.
161. Gratzke AL, Reimers K, Vogt PM, et al. Sensitising Breast Cancer Cells to Chemotherapy by Down Regulation of Lifeguard. *J Cancer Sci Ther.* 2014;6:411-416.
162. Shaukat U, Toor M, Ahmad B, et al. Genetic and Computational Analysis of Tgfb1 & Fgfr2 Polymorphism in Correlation to Breast Cancer Susceptibility in Pakistani Women. *J Cancer Sci Ther.* 2014;6:433-439.
163. Stoicescu M, Bungau S. Contraceptive Pills Consumption Risk Factor of the Breast Cancer Original Case Report. *Drug Des.* 2014;3:118.
164. Lagana L, Fobair P, Spiegel D. Targeting the Psychosexual Challenges Faced by Couples with Breast Cancer: Can Couples Group Psychotherapy Help? *J Women's Health Care.* 2014;3:205.
165. Labyak C, Daily K, Samiian L, et al. Preventing Breast Cancer Recurrence through a Tailored Lifestyle Intervention: The MyLIFE (My Lifestyle Intervention with Food and Exercise) Trial Rationale and Study Design. *J Clin Trials.* 2014;4:183.
166. Molina Y, Thompson B, Ceballos RM. Physician and Family Recommendations to Obtain a Mammogram and Mammography Intentions: The Moderating Effects of Perceived Seriousness and Risk of Breast Cancer. *J Women's Health Care.* 2014;3:199.
167. Zhang L, Yang C. Promise of Cyclin-Dependent Kinases 4/6 as Therapeutic Targets in Breast Cancer. *J Carcinog Mutagen.* 2014;5:191.
168. Rejeeth C, Nataraj B, Vivek R, et al. Biosynthesis of Silver Nanoscale Particles Using *Spirulina platensis* Induce Growth-Inhibitory Effect on Human Breast Cancer Cell Line MCF-7. *Med Aromat Plants.* 2014;3:163.
169. Khullar P, Datta NR, Venkadamani G, et al. Comparative Dosimetric Evaluation of Intensity Modulated Radiation Therapy versus Conventional Radiotherapy in Postoperative Radiotherapy of Breast Cancer. *J Nucl Med Radiat Ther.* 2014;5:189.
170. Pistelli M, Pagliacci A, Ballatore Z, et al. Using of Androgen Receptor Expression as a Novel Potential Biomarker in Predicting Survival of Women with Metastatic Triple Negative Breast Cancer. *J Cancer Sci Ther.* 2014;6: 388-393.
171. Oh B, Butow P, Boyle F, et al. Effects of Qigong on Quality of Life, Fatigue, Stress, Neuropathy, and Sexual Function in Women with Metastatic Breast Cancer: A Feasibility Study. *Int J Phys Med Rehabil.* 2014;2:217.
172. Cherif WT, Uhrhammer N, Ayed FB, et al. Does Consanguinity Protect Against Breast Cancer in Tunisian Population?. *Hereditary Genet.* 2014;3:130.
173. Hurley RM, Suman V, Daly M, et al. Assessment of Interest for Breast Cancer Prevention Trial Participation among BRCA Mutation Carriers. *Hereditary Genet.* 2014;3:127.

174. Shihua W. Targeting Aromatase and Estrogen Signaling for Breast Cancer. *J Nanomedicine Biotherapeutic Discov.* 2014;4:e128.
175. Liesheng L, Lei Y, Zhenshun S, et al. Comparison Study of E-cadherin Expression in Primary Breast Cancer and its Corresponding Metastatic Lymph Node. *J Cytol Histol.* 2014;5:248.
176. Itoi N, Abe H, Mori T, et al. Breath Alcohol Concentration in Japanese Breast Cancer Patients Following Alcohol-Containing Chemotherapeutic Agent Infusion. *J Pharmacovigilance.* 2014;2:138.
177. Kucuktulu E , Yurekli AF, Kucuktulu U, et al. A Comparison of Thyroid Dose Distribution in 3-D Conformal Radiotherapy and Tomotherapy in Patients with Breast Cancer. *J Nucl Med Radiat Ther.* 2014;5:173.
178. Spence R, DiSipio T, Schmitz K, et al. Is Unsupervised Exercise Following Breast Cancer Safe for All Women?. *Int J Phys Med Rehabil.* 2014;2:197.
179. Rahman MZ. Breast Cancer: Diagnosis Advanced. *Surgery Curr Res.* 2014;4:e112.
180. Bánhegyi RJ, Laczó I, Fülöp F, et al. The Role of Fulvestrant in the Treatment of Metastatic Breast Cancer: A Case Report. *J Steroids Hormon Sci.* 2014;5:131.
181. Pistelli M, Ballatore Z, De Lisa M, et al. Paclitaxel and Bevacizumab in First Line-Treatment Patients with HER-2 Negative Advanced Breast Cancer: Who could Benefit?. *Chemotherapy.* 2014;3:127.
182. Yu Q, Fan Y, Wu X. General Multiple Mediation Analysis With an Application to Explore Racial Disparities in Breast Cancer Survival. *J Biomet Biostat.* 2014;5:189.
183. Lwin MO. Examining Asian Women’s Motivations to Undergo Breast Cancer Screening. *J Women’s Health Care.* 2014;3:158.
184. Hafiyani L, Yokoyama S, Abdelhamed S, et al. Bufadienolides Overcome TRAIL Resistance in Breast Cancer Cells via JAK-STAT Pathway. *Altern Integr Med.* 2014;3:154.
185. Banning M. The Human Element of Breast Cancer: Insights from Pakistan. *Primary Health Care.* 2014;4:154.
186. Morisaki A, Hattori K, Kato Y, et al. Right Parasternal Cardiac Surgery after Radical Treatment of Left Breast Cancer. *J Cardiovasc Dis Diagn.* 2014;2:146.
187. Shi H, Zhang L, Qu Y, et al. Correlation between Id Genes Expressions and Histological Grade, Sonographic Findings in Breast Cancer. *J Cytol Histol.* 2014;S4:005.
188. Ragab AR, Farouk O, Afify MM, et al. The Role of Oxidative Stress in Carcinogenesis Induced By Metals in Breast Cancer Egyptian Females Sample at Dakahlia Governorate. *J Environ Anal Toxicol.* 2014;4:207.
189. Sakamoto Y. Bilateral Typical Femoral Fractures in a Patient with Metastatic Breast Cancer on Long-Term Bisphosphonate Therapy: A Case Report. *J Osteopor Phys Act.* 2014;2:110.
190. Brančíková D, Mechl Z, Adam Z, et al. Bone Markers in the Treatment of Cancer Related Bone Disease in Patients with Metastatic Breast Cancer. *J Cancer Sci Ther.* 2014;6:027-031.
191. Khan HMR, Saxena A, Shrestha A. Posterior Inference for White Hispanic Breast Cancer Survival Data. *J Biomet Biostat.* 2014;5: 183.
192. Chandra P, Suman P, Mukherjee M, et al. HER2 Protein Biomarker Based Sensor Systems for Breast Cancer Diagnosis. *J Mol Biomark Diagn.* 2014;5:e119.
193. Brentnall AR, Evans DG, Cuzick J. Value of Phenotypic and Single-Nucleotide Polymorphism Panel Markers in Predicting the Risk of Breast Cancer. *J Genet Syndr Gene Ther.* 2014;4:202.
194. Mahmud K. HRT with Cardiovascular and Breast Cancer Risk Reduction. *J Gen Pract.* 2014;1:131.
195. Carpenter RL, Lo HW. Regulation of Apoptosis by HER2 in Breast Cancer. *J Carcinogene Mutagene.* 2013;S7:003.
196. Hakkak R, Korourian S, Melnyk S. Obesity, Oxidative Stress and Breast Cancer Risk. *J Cancer Sci Ther.* 2013;5:e129.

197. Omene C, Kalac M, Wu J, et al. Propolis and its Active Component, Caffeic Acid Phenethyl Ester (CAPE), Modulate Breast Cancer Therapeutic Targets via an Epigenetically Mediated Mechanism of Action. *J Cancer Sci Ther.* 2013;5:334-342.
198. Anand M, Singh J, Siddiqui MKJ, et al. Organochlorine Pesticides in the Females Suffering from Breast Cancer and its Relation to Estrogen Receptor Status. *J Drug Metab Toxicol.* 2013;4:156.
199. Malik AA, Kiran T. Psychological Problems in Breast Cancer Patients: A Review. *Chemotherapy.* 2013;2:115.
200. Chiang JY, Chen DC. Drop Metastasis Seeding the Intramedullary Conus Medullaris in a Patient with Breast Cancer and Brain Metastasis. *Altern Integr Med.* 2013;2:136.